Biweekly Dosing News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Biweekly Dosing. Real-time updates on events, politics, business and more.

Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

June 5, 2023

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023

Noord Holland United States Rachel Kobos Satu Glawe Christie Corbett European Commission

Source: marketscreener.com

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

June 5, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...

Noord Holland United States Rachel Kobos Satu Glawe Christie Corbett Eastern Cooperative Oncology Group

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Biweekly Dosing News Today

Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI&#xAE; (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Janssen Presents Longer-Term Data for TECVAYLI&#xAE; (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Explore More Categories

Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma